Pfizer invests $8 million in start-up

A Boston start-up developing drugs targeting diabetes and obesity got a big infusion of capital from Pfizer Inc. this week.

Pfizer Venture Investments backed Rhythm Pharma with $8 million, joining other venture capitalists such as MPM Capital, Third Rock Ventures and New Enterprise Associates as backers, according to a report on the website FiercePharma.

The company's two drugs in development are still likely years from approval. But the company, led by Keith Gottesdiener, formerly of Merck, has raised $73 million in two years. "We are pleased to help Rhythm capitalize on its opportunities," said Pfizer's Barbara Dalton, vice president of venture capital.

Hide Comments

READER COMMENTS

Loading comments...
Hide Comments